The Announcement That Changed the Conversation
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. appeared on the Joe Rogan Experience and said what a lot of clinicians have been waiting to hear: he intends to reverse the FDA’s decision to restrict a group of peptides from compounding pharmacy production, and that the FDA is reviewing the status of multiple peptides currently on the Category 2 list.
If you have built peptide protocols around compounds like BPC-157, Thymosin Alpha-1, AOD-9604, CJC-1295, Selank, Semax, KPV, MOTS-C, or GHK-Cu, this announcement likely felt like vindication. These are compounds you have seen work in your patients—for tissue repair, immune regulation, metabolic support, gut healing—and for over two years, the legal pathway to prescribe many of them through compounding pharmacies has been functionally constrained.
Kennedy argued that the Category 2 placements were not supported by adequate safety data, in his view, and that the restrictions lacked transparency. He contended that by pulling these peptides away from compounding pharmacies, the FDA pushed patients toward unregulated gray-market vendors selling products with no quality oversight—exactly the opposite of what a safety-focused regulatory regime should produce.
The signal is clear. The formal rule change is not.
And that gap—between what has been said publicly and what has actually been codified in regulation—is where every modern clinician needs to be paying close attention right now.
What Actually Happened (and What Has Not)
Kennedy’s remarks on the podcast were significant, but they were remarks. As of this writing, no FDA rule has changed. No Federal Register notice has been issued broadly removing peptides from Category 2. No statute has been amended. A change in regulatory posture has been publicly signaled, and limited Category 2 removals have occurred, but a broad formal reclassification has not yet been proposed or finalized through the FDA’s usual notice-and-comment process.
This distinction matters enormously for your practice. As LumaLex Law, a firm specializing in regulated health businesses, has framed it: political commentary and regulatory action are not the same thing. The HHS Secretary oversees the FDA, which gives him influence over policy direction and enforcement priorities—but it does not give him the authority to unilaterally rewrite federal drug law.
If peptide regulation does change formally, it will happen through one of several mechanisms, each with different timelines and levels of legal certainty:
Enforcement Discretion
The FDA could deprioritize enforcement against specific Category 2 substances. This can happen relatively quickly—within weeks or months. But it does not change the statute, does not convert a restricted substance into an approved drug, and does not create a permanent safe harbor. It lowers enforcement pressure without eliminating legal risk.
Formal Reclassification
The FDA could revisit each substance’s categorization and formally move peptides from Category 2 to Category 1 through administrative review. This process takes months and may improve regulatory posture but does not automatically authorize compounding in all contexts.
Full Rulemaking
A durable, legally secure change would require review of safety data, advisory committee input, publication in the Federal Register, and compliance with the Administrative Procedure Act. This process can take a year or more.
The most likely near-term outcome is enforcement discretion—which is meaningful but not the same as legality. The timing of any formal FDA action is uncertain and could range from months to longer. For clinicians and compounding pharmacies, the underlying legal framework remains intact unless formally amended.
How We Got Here: The Category 2 Story
To understand why Kennedy’s announcement matters, you need the backstory.
In late 2023, the FDA placed 19 peptides on the Category 2 list of bulk drug substances—a designation for compounds the agency considers to present significant safety risks. This led most compliant compounding pharmacies to stop preparing these peptides for routine patient use under Section 503A, because FDA deemed them higher-risk based on concerns about immunogenicity, manufacturing impurities, and a lack of large-scale human clinical trial data.
The 19 peptides placed on the restricted list included BPC-157, Cathelicidin LL-37, Emideltide (DSIP), Epitalon, GHK-Cu (injectable), GHRP-2, GHRP-6, Ipamorelin acetate, Kisspeptin-10, KPV, Melanotan II, PEG-MGF, MOTS-C, Semax, Thymosin beta-4 fragment, AOD-9604, CJC-1295, Selank acetate, and Thymosin alpha-1.
The clinical and legal community pushed back. Compounding pharmacy trade groups filed lawsuits arguing that the FDA overreached—that the agency lacked adequate safety signals to justify the scope of the restrictions and was not transparent about the underlying safety data. At least some of these lawsuits have reached settlement.
The only concrete, documented regulatory action so far occurred in September 2024, when five peptides—CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank—were removed from Category 2 and referred to the Pharmacy Compounding Advisory Committee (PCAC) for review. That referral is the first step toward potential Category 1 eligibility, but it does not equal Category 1 status and does not guarantee it.
Kennedy’s February 2026 statement signals that the administration intends to broaden this trajectory. However, the FDA has not publicly specified the scope of any upcoming reclassification, committed to a defined number of peptides, or provided a binding timeline. The specific peptides that may be considered for Category 1 eligibility, and the timeline for any formal FDA action, remain uncertain.
What This Means for Your Practice
If you are a functional, integrative, or longevity clinician, this is the most significant shift in regulatory posture around peptide access since the 2023 restrictions were imposed. But it does not mean the guardrails are gone. It means they are being repositioned.
What Category 1 Reclassification Would Mean
Category 1 status means a compound is eligible for use by licensed compounding pharmacies to prepare individualized medications under a physician’s prescription. If peptides are formally moved to Category 1, it would create a legitimate, quality-controlled pathway for your patients to access them through licensed channels with proper oversight.
What Reclassification Would Not Mean
It would not be FDA approval. These peptides would remain unapproved for specific indications. They would still be off-label therapeutics for most clinical applications. They would still require informed consent, clinical justification, and monitoring. And Category 1 status would not retroactively validate the gray-market supply chains that emerged during the restriction period—RUO-labeled peptides, direct-from-lab vendors, and online “research chemical” suppliers remain outside the legal framework regardless.
Kennedy’s own argument reinforces this point: he argued that restoring compounding access through ethical suppliers is the safer path. That reasoning supports the case for rigorous sourcing standards in your practice—not for treating every peptide as cleared for use.
Building a Peptide Program That Survives Either Outcome
The smart move right now is not to wait for the formal rule change. It is to build a practice framework that works whether reclassification happens in the near term, takes significantly longer, or gets delayed by legal challenges. Here is how.
Pillar 1: Map Your Formulary to the Emerging Regulatory Reality
Use the shifting regulatory landscape as your organizing principle, but tier your peptides by legal certainty rather than clinical enthusiasm. This is an internal, practice-level risk stratification—not a statement of regulatory fact.
Tier 1 – Higher Confidence
Peptides that have already been removed from Category 2 and referred to PCAC for review (CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, Selank), plus others with favorable early clinical experience in integrative and longevity practice, such as BPC-157, GHK-Cu, KPV, MOTS-C, and Semax. These peptides have increasing clinical use but still limited formal human trial data and unresolved FDA safety questions. They may be considered for Category 1 eligibility pending FDA and PCAC review. Prescribe only through pharmacy partners who can demonstrate current compliance with each substance’s legal status.
Tier 2 – Watch and Prepare
Peptides that remain on the Category 2 list with less clarity about their regulatory trajectory. Build your protocols, consent language, and monitoring frameworks now so you are ready to move if and when their status changes formally.
Tier 3 – Do Not Prescribe
Peptides with more concerning adverse event reports or stronger FDA safety objections are likely to remain in Category 2, though the specific list is not yet defined by the FDA. Any substance still only accessible via RUO labeling or non-pharmacy vendors stays out of patient care regardless.
Capture this as a one-page Peptide Formulary Policy that any team member, pharmacy partner, or regulator can read. It turns a moving target into a shared map—and it demonstrates that your practice is making deliberate, documented decisions rather than reacting to headlines.
Pillar 2: Lock Down Your Pharmacy Partnerships
If reclassification restores compounding eligibility, the next question is: who is compounding these peptides, and to what standard?
Limit prescribing to 503A and 503B pharmacy partners who can demonstrate GMP-compliant peptide APIs with certificates of analysis, peptide-specific SOPs and quality controls, a clear understanding of current BDS categories, and recent clean inspection history. Codify the non-negotiables: no RUO vials in patient care, no direct-from-lab APIs repackaged in clinic, and no purchasing from online research peptide vendors for human use.
This is the clinical operationalization of Kennedy’s own argument—that patients deserve access through ethical suppliers. Make sure your suppliers actually meet that standard.
Pillar 3: Elevate Consent, Documentation, and Monitoring
Reclassification—if and when it occurs—would not change the fact that these are unapproved compounds. Every peptide encounter should document:
Regulatory status: compounded under current FDA category status, not FDA-approved. Patients must understand this distinction.
Alternatives considered: FDA-approved options discussed and why a compounded peptide was chosen (access, intolerance, cost, mechanistic rationale).
Monitoring plan: baseline and follow-up labs, clinical endpoints, and whether therapy is time-bounded or open-ended.
Informed consent: that the patient understands the off-label, compounded nature of the therapy, the fact that human clinical trial data remains limited for many of these peptides, and the uncertainty around long-term safety.
Layer on an adverse event log specific to peptide products that tracks pharmacy, batch, and clinical events. If an FDA communication or pharmacy issue surfaces, you respond with data—not a scramble through charts.
A Note on GLP-1s: A Separate Track
Kennedy’s announcement focused on Category 2 peptides, not GLP-1 compounding. The GLP-1 landscape continues on its own regulatory track, and it is tightening.
The FDA has continued to issue warning letters targeting non-FDA-approved GLP-1 drugs, including compounded semaglutide marketed as alternatives to branded products. Semaglutide and tirzepatide can only be compounded while the corresponding approved products remain on the official drug shortage list. The shortage designations for tirzepatide were lifted in late 2024 and for semaglutide in early 2025, after which compounding “essentially a copy” of those drugs became subject to enforcement action. The FDA has signaled increased enforcement against non-approved GLP-1 products in 2025 and 2026.
Do not conflate the Category 2 peptide reclassification discussion with the GLP-1 compounding question. They are governed by different rules, different enforcement postures, and different timelines.
How AI Helps You Navigate This
In previous issues, we framed AI as a pattern-recognition and synthesis layer for diagnostics and documentation. The peptide reclassification discussion adds a new dimension: regulatory intelligence in a fast-moving, legally ambiguous environment.
AI is not here to tell you whether BPC-157 works. It is here to compress the work required to practice peptides inside the guardrails—especially when those guardrails are shifting in real time.
Important caveat: Use AI to aggregate and summarize relevant sources, then have you and your legal counsel interpret and apply that information to your practice. AI outputs are research tools, not legal advice.
AI as Regulatory Intelligence
You cannot manually track every FDA update, state board memo, legal analysis, and enforcement action relevant to peptides. But you can build a system that does:
Build a peptide regulation workspace. Feed in the FDA bulk substance lists, Kennedy’s public statements, the LumaLex Law analysis on what has and hasn’t changed, relevant state board guidance, and your pharmacy partners’ compliance documentation. Ask your AI copilot to aggregate and summarize the current regulatory landscape for specific peptides, noting areas of uncertainty.
Draft your Peptide Formulary Policy with AI. Provide your current peptide list, known regulatory constraints, and your tiered framework. Let AI generate the first-pass mapping. Then you and counsel review, correct, and finalize it.
Run a regulatory drift check every two weeks during this transition. Prompt: “Compare our current peptide formulary against any FDA announcements, Federal Register notices, or state-level changes since the last check. Flag molecules whose category, enforcement posture, or compounding eligibility may have shifted.” Then review with counsel before acting.
You are not outsourcing clinical or legal judgment. You are offloading the surveillance work that no solo clinician can sustain at the pace this landscape is moving.
AI as a Consent and Documentation Engine
Informed consent forms: Generate consent documents that explain current regulatory status (Category 1 vs. Category 2, not FDA-approved), the limited human trial data for specific peptides, the risks, and the monitoring plan. Edit once, reuse across similar encounters.
Patient counseling scripts: Draft language for the conversations you will be having: “What the regulatory change means and what it doesn’t,” “Why we will not source from the vendors you may have been using,” and “What ‘unapproved’ means in this context.”
Structured note templates: Build peptide visit macros that capture indication, alternatives considered, rationale, regulatory status, consent, and monitoring—generated from the chart, then clinician-edited.
AI as a Longitudinal Safety Monitor
As the regulatory posture shifts and more patients access peptides through legitimate channels, AI’s pattern-recognition layer becomes critical:
Panel-level safety scans: “Show me all patients on BPC-157 whose liver enzymes, hsCRP, or fasting glucose have worsened by more than Y% over 90 days.”
Pre-visit synthesis: For peptide follow-ups, generate a one-page brief: timeline of therapy, lab trends, body composition changes, symptom scores, and any adverse events. Walk into the room with the full clinical story.
Batch-level tracking: “List patients on compounded peptides from Pharmacy X with any reported adverse events, sorted by product and batch number.” If a quality issue surfaces, you can act immediately.
The Position
Kennedy’s announcement represents a significant and welcome shift in the direction of peptide access. For clinicians who have seen these compounds help patients—and who watched a broad regulatory action push patients toward unregulated vendors—the intent behind this reclassification effort aligns with what functional and integrative medicine has long argued: that informed clinicians working with quality-controlled compounding pharmacies are the safest pathway for patients to access emerging therapies.
But intent is not law. And the gap between announcement and implementation is where practices get exposed.
The modern clinician who thrives in this next phase will not be the one who rushes to prescribe everything the moment a podcast episode airs. It will be the one who has a tiered formulary ready, pharmacy partnerships vetted, consent language drafted, and monitoring systems in place—so that when formal regulatory changes are published, the practice can move immediately, with full legal and clinical defensibility.
AI will not save a disorganized peptide program. It will amplify whatever structure you give it. Build the structure now.
How I AI: Your Peptide Reclassification Workflow
Here is a practical sequence you can start this week:
1. Upload the regulatory spine. Drop the current FDA Category 2 list, Kennedy’s public statements, the LumaLex Law analysis on what has and hasn’t changed, your state board’s current compounding guidance, and the September 2024 PCAC referral documentation into your AI workspace.
2. Generate your tiered formulary draft. Prompt: “Here is our current peptide list and the current regulatory landscape. Map each to Tier 1 (higher confidence for near-term reclassification), Tier 2 (watch and prepare), or Tier 3 (do not prescribe), and explain the rationale in one sentence each. Note: this is an internal risk stratification, not a regulatory determination.”
3. Draft updated consent and note language. Prompt: “Using this formulary and framework, draft an informed consent template for compounded peptides that distinguishes Category 1 eligibility from FDA approval and notes limited human trial data, and a SOAP note template that captures indication, alternatives, rationale, regulatory status, consent, and monitoring.”
4. Set a biweekly regulatory check during the transition period. Create a standing task: “Every two weeks, compare our formulary against any new FDA announcements, Federal Register notices, PCAC updates, or state-level guidance. Flag any misalignments and recommend updates for review with counsel.”
5. Vet your pharmacy partnerships. Prompt: “Draft a pharmacy due diligence questionnaire covering GMP compliance, Certificate of Analysis practices, peptide-specific SOPs, BDS category awareness, and most recent inspection results.” Send it to every compounding pharmacy you plan to work with.
The regulatory landscape for peptides is shifting—but it is shifting into a framework, not a free-for-all. The clinicians who position themselves inside that framework now will be the ones who build sustainable, defensible, patient-centered peptide programs that last.
Feel like your practice is being held back by your tech? That means it’s time you check out Vibrant, the AI-powered, all-in-one EHR built specifically for personalized medicine. Schedule a demo with our team to learn more about how we can help you extend your clinical brain and deliver great personalized care.
This Week in Clinical AI
This week underscores a new reality in healthcare AI: consumer tools are racing into patients’ hands while regulators and clinicians grapple with how — and where — AI should safely participate in care.
AI platform for surgical recovery wins FDA breakthrough designation. Recovry.ai received FDA Breakthrough Device designation for its AI platform designed to monitor and guide post-surgical recovery. The system analyzes patient-reported outcomes, wearable data, and recovery trajectories to flag complications earlier and personalize recovery protocols. For clinicians, this signals a growing category of AI tools focused on longitudinal care and recovery optimization, not just diagnosis or documentation.
AI alone won’t solve antibiotic resistance. Despite excitement around AI-driven drug discovery, experts warn that technology alone cannot fix the global antibiotic resistance crisis, according to new reporting in STAT. AI may accelerate discovery of new compounds, but economic incentives for antibiotic development remain weak, and stewardship challenges persist. The takeaway: AI can speed up discovery, but structural healthcare problems still require policy and economic solutions.
ChatGPT Health struggles to recognize medical emergencies. A recent analysis found that ChatGPT’s health features sometimes failed to recommend emergency care in simulated urgent scenarios, raising concerns about relying on consumer AI for medical triage. While tools like ChatGPT Health aim to help users interpret symptoms and records, researchers warn that inaccurate triage advice could delay necessary treatment. For clinicians, this highlights a likely new reality: patients arriving with AI-generated interpretations that still require careful clinical validation.
👋 Welcome New Readers
The Modern Clinician is written for functional, integrative, and longevity-focused physicians who want to scale their impact and deliver cutting-edge care.
If you liked this one, share it with a colleague! We appreciate you spreading the word.
To learn more about the why behind this newsletter, start with our first post introducing The Modern Clinician.